Drug name - Lexiscan

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6403567 ASTELLAS N-pyrazole A2A adenosine receptor agonists
Apr, 2022

(5 months ago)

US8106183 ASTELLAS Process for preparing an A2A-adenosine receptor agonist and its polymorphs
Feb, 2027

(4 years from now)

CN101379073A ASTELLAS Method For Preparing An A2A-Adenosine Receptor Agonist And Its Polymorphs
Apr, 2013

(9 years ago)

CN102260311A ASTELLAS Method For The Preparation Of A Type 2A Adenosine Receptor Agonist And Its Polymorphs Thing
Mar, 2015

(7 years ago)

CN1358191A ASTELLAS N-Pyrazole A
Jun, 2020

(2 years ago)

CN1167709C ASTELLAS N-Pyrazole A
Jun, 2020

(2 years ago)

EP1189916A2 ASTELLAS N-Pyrazole A 2A Receptor Agonists
Jun, 2025

(2 years from now)

EP1189916B1 ASTELLAS N-Pyrazole A 2A Receptor Agonists
Jun, 2025

(2 years from now)

EP1989214B1 ASTELLAS Process For Preparing An A2A-Adenosine Receptor Agonist And Its Polymorphs
Feb, 2027

(4 years from now)

EP1989214A1 ASTELLAS Process For Preparing An A2A-Adenosine Receptor Agonist And Its Polymorphs
Feb, 2027

(4 years from now)

EP1989214B8 ASTELLAS Process For Preparing An A2A-Adenosine Receptor Agonist And Its Polymorphs
Feb, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47301 ASTELLAS Process for preparing an A2A-adenosine receptor agonist and its polymorphs Feb, 2027

(4 years from now)

Drugs and Companies using REGADENOSON ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
0.4MG/5ML (0.08MG/ML) SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.